Citadel Advisors
MIRM icon

Citadel Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Citadel Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,800
Closed -$1.52M – 13540
2025
Q3 		$1.52M Sell
20,800
-100
-0.5% -$6.36K ﹤0.01% 6638
2025
Q2 		$1.06M Sell
20,900
-6,100
-23% -$272K ﹤0.01% 6949
2025
Q1 		$1.22M Buy
27,000
+5,100
+23% +$240K ﹤0.01% 6525
2024
Q4 		$906K Sell
21,900
-7,900
-27% -$329K ﹤0.01% 7249
2024
Q3 		$1.16M Buy
29,800
+20,000
+204% +$798K ﹤0.01% 6571
2024
Q2 		$335K Sell
9,800
-4,900
-33% -$128K ﹤0.01% 8914
2024
Q1 		$369K Sell
14,700
-7,200
-33% -$198K ﹤0.01% 9019
2023
Q4 		$646K Buy
21,900
+12,600
+135% +$381K ﹤0.01% 7553
2023
Q3 		$294K Sell
9,300
-1,600
-15% -$43.8K ﹤0.01% 9218
2023
Q2 		$282K Buy
10,900
+7,400
+211% +$197K ﹤0.01% 9182
2023
Q1 		$84.1K Sell
3,500
-3,500
-50% -$79.8K ﹤0.01% 11499
2022
Q4 		$137K Buy
+7,000
New +$138K ﹤0.01% 10752
2022
Q3 		– Sell
-14,600
Closed -$284K – 13217
2022
Q2 		$284K Buy
14,600
+1,800
+14% +$42.5K ﹤0.01% 9925
2022
Q1 		$282K Sell
12,800
-9,000
-41% -$184K ﹤0.01% 10735
2021
Q4 		$348K Sell
21,800
-8,600
-28% -$134K ﹤0.01% 10585
2021
Q3 		$606K Buy
+30,400
New +$494K ﹤0.01% 9396

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors's MIRM Position: Q1 2026 in Review

Citadel Advisors increased its Mirum Pharmaceuticals (MIRM) stake by 25% in Q1 2026, buying an estimated $19.9M and bringing the position to 1,052,048 shares worth $97.2M. The position accounts for 0.02% of the portfolio, ranked #826.

Citadel Advisors first reported a position in MIRM in Q2 2020 and has held it in 22 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Citadel Advisors held 1,052,048 shares of Mirum Pharmaceuticals worth $97.2M as of Q1 2026.
  • Citadel Advisors bought 211,828 Mirum Pharmaceuticals shares in Q1 2026, an estimated $19.9M.
  • Mirum Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #826 holding.
  • Citadel Advisors first reported a position in Mirum Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.